Main Article Content
Treatments for ocular surface disease have evolved significantly over the past several years. Sutureless amniotic membranes are easy to insert in the office, and they give practitioners the ability to monitor healing without interfering with the penetration of ophthalmic medications. With their ability to reduce inflammation, prevent scarring, and enhance epithelial proliferation, AM should be considered as a viable treatment option for managing patients with ocular surface disease.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
2. Rennie K, Gruslin A, Hengstschla¨ger M, et al. Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine. Stem Cells Int 2012; 2012:721538.
3. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci 2001; 42:1539–1546.
4. Tseng SCG, Espana EM, Kawakita T, et al. How does amniotic membrane work? Ocul Surf 2004; 2:177–187.
5. Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. Eye Contact Lens 2009; 35:172–175.
6. Ijiri S1, Kobayashi A, Sugiyama K, et al. Evaluation of visual acuity and color vision in normal human eyes with a sutureless temporary amniotic membrane patch. Am J Ophthalmol. 2007;144(6):938-942.